COVID - Spplement VACCINE ADJ DISCOVERY PROGRAM (VADP)

新冠肺炎 - 补充疫苗调整发现计划 (VADP)

• 批准号: 10301500
• 负责人: JAY EVANS
• 金额: $ 369.97万
• 依托单位: UNIVERSITY OF MONTANA
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2020-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10301500
• 关键词: 2019-nCoV; Adjuvant; Antibodies; Antibody titer measurement; Antigens; Baculovirus Expression System; Cells; Cellular Immunity; Contracts; Development; Disease; Equipment; Evaluation; Ferrets; Formulation; Human; Human Resources; Humoral Immunities; Infection; Lead; Length; Modeling; Mucous Membrane; Mus; Particle Size; Production; Proteins; Recombinant Proteins; Recombinants; Resources; SARS coronavirus; Serum; Side; T cell response; Testing; Transgenic Mice; Vaccine Adjuvant; Vaccine Production; Vaccines; coronavirus disease; cytokine; effector T cell; immunogenicity; in vivo; in vivo evaluation; programs; receptor; receptor binding; vaccine candidate; vaccine efficacy; vaccine evaluation; vaccine safety

To identify the optimal adjuvant for recombinant SARS-CoV2 vaccines, and to identify correlates of protection against SARS-CoV2 infection or disease, experimental SARS-CoV2 vaccines will be formulated with a panel of different vaccine adjuvants and tested side-by-side for immunogenicity and efficacy.

为了确定重组 SARS-CoV2 疫苗的最佳佐剂，并确定预防 SARS-CoV2 感染或疾病的相关性，实验性 SARS-CoV2 疫苗将采用一组不同的疫苗佐剂配制，并并排测试免疫原性和功效。